Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) last week outlined progress on its lead oncology asset HMBD-002, positioning the immunotherapy program to move into Phase II clinical testing following ...
The very first patient would receive the first clinical doses of HMBD-001, the first cancer treatment from Hummingbird Bioscience. Piers Ingram, the cofounder and CEO of the company, was nervous, but ...
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has launched a 2-for-5 non-renounceable entitlement offer to raise up to about $2.2 million before costs, with proceeds earmarked to advance its lead ...
HOUSTON and SINGAPORE, Sept. 13, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today ...
HOUSTON and SINGAPORE, Feb. 8, 2022 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in ...
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in ...
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has secured acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 17–22, ...
SAN DIEGO & HOUSTON & SINGAPORE--(BUSINESS WIRE)--Hummingbird Bioscience (“Hummingbird Bio”), a data-driven precision biotherapeutics company discovering and developing transformative biologic ...
Jensen Huang's GTC keynote wasn't about new chips. It was a declaration Nvidia wants to own AI's inference phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results